Yan Tang1, Souheil El-Chemaly1, Angelo Taveira-Dasilva2, Hilary J Goldberg1, Shefali Bagwe1, Ivan O Rosas1, Joel Moss2, Carmen Priolo3, Elizabeth P Henske1. 1. Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 2. Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 3. Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: Carmen_priolo@dfci.harvard.edu.
Abstract
BACKGROUND: Lymphangioleiomyomatosis (LAM), a destructive lung disease that affects primarily women, is caused by loss-of-function mutations in TSC1 or TSC2, leading to hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells. Based on the hypothesis that simultaneous inhibition of mTORC1 and autophagy would limit the availability of critical nutrients and inhibit LAM cells, we conducted a phase 1 clinical trial of sirolimus and hydroxychloroquine for LAM. Here, we report the analyses of plasma metabolomic profiles from the clinical trial. METHODS: We analyzed the plasma metabolome in samples obtained before, during, and after 6 months of treatment with sirolimus and hydroxychloroquine, using univariate statistical models and machine learning approaches. Metabolites and metabolic pathways were validated in TSC2-deficient cells derived from patients with LAM. Single-cell RNA-Seq was employed to assess metabolic enzymes in an early-passage culture from an LAM lung. RESULTS: Metabolomic profiling revealed changes in polyamine metabolism during treatment, with 5'-methylthioadenosine and arginine among the most highly upregulated metabolites. Similar findings were observed in TSC2-deficient cells derived from patients with LAM. Single-cell transcriptomic profiling of primary LAM cultured cells revealed that mTORC1 inhibition upregulated key enzymes in the polyamine metabolism pathway, including adenosylmethionine decarboxylase 1. CONCLUSIONS: Our data demonstrate that polyamine metabolic pathways are targeted by the combination of rapamycin and hydroxychloroquine, leading to upregulation of 5'-methylthioadenosine and arginine in the plasma of patients with LAM and in TSC2-deficient cells derived from a patient with LAM upon treatment with this drug combination. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov. Partners Human Research Committee, protocol No. 2012P000669.
BACKGROUND:Lymphangioleiomyomatosis (LAM), a destructive lung disease that affects primarily women, is caused by loss-of-function mutations in TSC1 or TSC2, leading to hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells. Based on the hypothesis that simultaneous inhibition of mTORC1 and autophagy would limit the availability of critical nutrients and inhibit LAM cells, we conducted a phase 1 clinical trial of sirolimus and hydroxychloroquine for LAM. Here, we report the analyses of plasma metabolomic profiles from the clinical trial. METHODS: We analyzed the plasma metabolome in samples obtained before, during, and after 6 months of treatment with sirolimus and hydroxychloroquine, using univariate statistical models and machine learning approaches. Metabolites and metabolic pathways were validated in TSC2-deficient cells derived from patients with LAM. Single-cell RNA-Seq was employed to assess metabolic enzymes in an early-passage culture from an LAM lung. RESULTS: Metabolomic profiling revealed changes in polyamine metabolism during treatment, with 5'-methylthioadenosine and arginine among the most highly upregulated metabolites. Similar findings were observed in TSC2-deficient cells derived from patients with LAM. Single-cell transcriptomic profiling of primary LAM cultured cells revealed that mTORC1 inhibition upregulated key enzymes in the polyamine metabolism pathway, including adenosylmethionine decarboxylase 1. CONCLUSIONS: Our data demonstrate that polyamine metabolic pathways are targeted by the combination of rapamycin and hydroxychloroquine, leading to upregulation of 5'-methylthioadenosine and arginine in the plasma of patients with LAM and in TSC2-deficient cells derived from a patient with LAM upon treatment with this drug combination. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov. Partners Human Research Committee, protocol No. 2012P000669.
Authors: Souheil El-Chemaly; Angelo Taveira-Dasilva; Hilary J Goldberg; Elizabeth Peters; Mary Haughey; Don Bienfang; Amanda M Jones; Patricia Julien-Williams; Ye Cui; Julian A Villalba; Shefali Bagwe; Rie Maurer; Ivan O Rosas; Joel Moss; Elizabeth P Henske Journal: Chest Date: 2017-02-10 Impact factor: 9.410
Authors: Francis X McCormack; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Charlie Strange; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Lisa R Young; Brent W Kinder; Gregory P Downey; Eugene J Sullivan; Thomas V Colby; Roy T McKay; Marsha M Cohen; Leslie Korbee; Angelo M Taveira-DaSilva; Hye-Seung Lee; Jeffrey P Krischer; Bruce C Trapnell Journal: N Engl J Med Date: 2011-03-16 Impact factor: 91.245
Authors: Anthony M Lamattina; Angelo Taveira-Dasilva; Hilary J Goldberg; Shefali Bagwe; Ye Cui; Ivan O Rosas; Joel Moss; Elizabeth P Henske; Souheil El-Chemaly Journal: Chest Date: 2018-08-23 Impact factor: 9.410
Authors: Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Natalia Martín-Martín; Sonia Fernandez-Ruiz; James D Sutherland; Michelle Clasquin; Julen Tomas-Cortazar; Jose Jimenez; Ines Torres; Phong Quang; Pilar Ximenez-Embun; Ruzica Bago; Aitziber Ugalde-Olano; Ana Loizaga-Iriarte; Isabel Lacasa-Viscasillas; Miguel Unda; Verónica Torrano; Diana Cabrera; Sebastiaan M van Liempd; Ylenia Cendon; Elena Castro; Stuart Murray; Ajinkya Revandkar; Andrea Alimonti; Yinan Zhang; Amelia Barnett; Gina Lein; David Pirman; Ana R Cortazar; Leire Arreal; Ludmila Prudkin; Ianire Astobiza; Lorea Valcarcel-Jimenez; Patricia Zuñiga-García; Itziar Fernandez-Dominguez; Marco Piva; Alfredo Caro-Maldonado; Pilar Sánchez-Mosquera; Mireia Castillo-Martín; Violeta Serra; Naiara Beraza; Antonio Gentilella; George Thomas; Mikel Azkargorta; Felix Elortza; Rosa Farràs; David Olmos; Alejo Efeyan; Juan Anguita; Javier Muñoz; Juan M Falcón-Pérez; Rosa Barrio; Teresa Macarulla; Jose M Mato; Maria L Martinez-Chantar; Carlos Cordon-Cardo; Ana M Aransay; Kevin Marks; José Baselga; Josep Tabernero; Paolo Nuciforo; Brendan D Manning; Katya Marjon; Arkaitz Carracedo Journal: Nature Date: 2017-06-28 Impact factor: 49.962
Authors: David Kapfhamer; James McKenna; Caroline J Yoon; Tracy Murray-Stewart; Robert A Casero; Michael J Gambello Journal: Hum Mol Genet Date: 2020-08-11 Impact factor: 6.150
Authors: Margaret E Torrence; Michael R MacArthur; Aaron M Hosios; Alexander J Valvezan; John M Asara; James R Mitchell; Brendan D Manning Journal: Elife Date: 2021-03-01 Impact factor: 8.140
Authors: Carmen Herranz; Francesca Mateo; Alexandra Baiges; Gorka Ruiz de Garibay; Alexandra Junza; Simon R Johnson; Suzanne Miller; Nadia García; Jordi Capellades; Antonio Gómez; August Vidal; Luis Palomero; Roderic Espín; Ana I Extremera; Eline Blommaert; Eva Revilla-López; Berta Saez; Susana Gómez-Ollés; Julio Ancochea; Claudia Valenzuela; Tamara Alonso; Piedad Ussetti; Rosalía Laporta; Antoni Xaubet; José A Rodríguez-Portal; Ana Montes-Worboys; Carlos Machahua; Jaume Bordas; Javier A Menendez; Josep M Cruzado; Roser Guiteras; Christophe Bontoux; Concettina La Motta; Aleix Noguera-Castells; Mario Mancino; Enrique Lastra; Raúl Rigo-Bonnin; Jose C Perales; Francesc Viñals; Alvaro Lahiguera; Xiaohu Zhang; Daniel Cuadras; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Harilaos Filippakis; Razq Hakem; Chiara Gorrini; Marc Ferrer; Aslihan Ugun-Klusek; Ellen Billett; Elżbieta Radzikowska; Álvaro Casanova; María Molina-Molina; Antonio Roman; Oscar Yanes; Miquel A Pujana Journal: EMBO Mol Med Date: 2021-08-11 Impact factor: 12.137
Authors: Dinesh Kumar Barupal; Priyanka Mahajan; Sadjad Fakouri-Baygi; Robert O Wright; Manish Arora; Susan L Teitelbaum Journal: Environ Int Date: 2022-04-18 Impact factor: 13.352